This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Health House International Valuation

Is HHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HHI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HHI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HHI?

Key metric: As HHI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HHI. This is calculated by dividing HHI's market cap by their current revenue.
What is HHI's PS Ratio?
PS Ratio	0.05x
Sales	AU$19.26m
Market Cap	AU$891.12k

HHI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-0.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HHI's PS Ratio compare to its peers?

The above table shows the PS ratio for HHI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	n/a

Price-To-Sales vs Peers: HHI is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does HHI's PS Ratio compare vs other companies in the AU Healthcare Industry?

0 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	n/a	6.9%
	n/a	n/a	n/a

0 Companies		Estimated Growth	Market Cap
Industry Avg.	n/a	26.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: HHI is good value based on its Price-To-Sales Ratio (0x) compared to the Australian Healthcare industry average (1.1x)

Price to Sales Ratio vs Fair Ratio

What is HHI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HHI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.05x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HHI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$127.8m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.08

5.9%

28.7%

Healius

AU$969.4m

Provides specialty diagnostic services to consumer and practitioners in Australia.

HLS

AU$1.33

-16.1%

-27.9%

Cogstate

AU$170.9m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.98

2.1%

-32.5%